INVA vs RGLD
INVA: A diversified biopharmaceutical company combining respiratory royalties from GSK blockbusters (BREO, ANORO) with a growing critical care and infectious disease platform (GIAPREZA, XACDURO, ZEVTERA, NUZOLVENCE). RGLD: Royal Gold is a leading precious metals royalty and streaming company that provides exposure to gold, silver, and copper production without the operational risks or capital intensity of mining.
Side-by-side fundamentals
| Metric | INVA | RGLD | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $21.30 | $201.02 | |
| Market cap as of 2026-08-01 | $1.6B | $17.1B | |
| P/E as of 2026-08-01 | 3.08 | 26.46 | INVA lower |
| PEG as of 2026-08-01 | n/a | 0.62 | |
| Net margin as of 2026-08-01 | +119.9% | +48.5% | INVA higher |
| Gross margin as of 2026-08-01 | +73.7% | +86.5% | RGLD higher |
| Operating margin as of 2026-08-01 | +38.1% | +62.2% | RGLD higher |
| ROE as of 2026-08-01 | +47.6% | +11.9% | INVA higher |
| ROA as of 2026-08-01 | +32.4% | +9.4% | INVA higher |
| Debt / equity as of 2026-08-01 | 0.19 | 0.08 | RGLD lower |
| Revenue growth (YoY) as of 2026-08-01 | +13.8% | +71.0% | RGLD higher |
| Revenue CAGR (3y) SEC XBRL | +7.5% | +19.5% | RGLD higher |
| Dividend yield as of 2026-08-01 | n/a | +0.9% | |
| Dividend streak (yrs) SEC XBRL | 0 | 5 | RGLD higher |
| Beta as of 2026-08-01 | 0.35 | 0.46 | |
| 1-year return as of 2026-07-27 close | +13.8% | +29.7% | RGLD higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.